Mercury Systems (MRCY) Q4 2026 Earnings Call Transcript

Mercury Systems reported record Q4 bookings of $660M (+93.1% YoY) and revenue of ~$290M (+6.1% organically), driving adjusted EBITDA to $49M with a 16.7% margin (highest in FY26). For FY26, revenue rose to $984M (+7.9% organic) and adjusted EBITDA grew 25.7% to $150M (15.3% margin), while free cash flow was $68M and net debt fell 19.5% to $227M after a $150M revolver repayment. FY27 guidance calls for revenue approaching $1.1B (nearly 10% YoY) and adjusted EBITDA approaching $200M (nearly 30% YoY growth), though free cash flow conversion is guided to ~35% vs a 50% long-term target due to planned automation/inventory investments. Management also cited a strategic Palantir AI partnership to improve material planning and factory optimization to enhance backlog conversion.

Analysis

MRCY is shifting from a “keep the line running” story to a conversion story: the important variable is not backlog size, but whether higher-visibility orders let management monetize fixed costs without another round of working-capital drag. If execution holds, the mix shift toward production should expand EBITDA faster than revenue over the next 2-4 quarters, which usually supports multiple expansion in a defense niche name that had been valued like a troubleshooting situation.

The second-order effect is that better scheduling and inventory planning can matter more than the Palantir branding. If software helps reduce expedite costs and overtime, that is a margin lever; if it merely accelerates materials purchases, the near-term cash-flow optics can actually get worse before they get better. International delivery normalization is another swing factor: the reported growth profile could look choppy for 1-2 quarters even if end demand is intact, so the market may need to underwrite the thesis on forward conversion rather than clean near-term EPS.

The contrarian risk is that investors may be overweighting the backlog headline and underweighting the cash conversion penalty from deliberate inventory builds. In defense electronics, book-to-bill spikes often fade before revenue catches up, and if FY27 free-cash-flow conversion fails to inflect, the stock can de-rate even with decent EBITDA growth. Falsifiers: a guide-down in FY27 revenue/EBITDA, any sign that backlog is not converting by mid-year, or another quarter where working capital consumes most of operating profit.

Key Decisions for Investors

• Long MRCY on any post-print consolidation; use a 3-6 month horizon and target a re-rating if management proves Q1/Q2 backlog conversion and EBITDA margin progression. Risk/reward is attractive if the market moves from "show me" to "pay me" on execution.
• Buy MRCY Jan-2027 call spreads instead of outright calls to express upside to margin expansion while capping downside if free-cash-flow conversion stays weak. This is the cleaner way to own the operating leverage story without paying for an aggressive cash-flow ramp.
• Pair trade: long MRCY / short ITA or XAR for 1-3 months as a relative-value bet that niche defense electronics with visible backlog outperforms the broader defense basket. The position works best if the market starts differentiating conversion quality from simple defense exposure.
• Do not chase PLTR on this headline alone; treat the partnership as an operational option, not a financial contribution, until there is evidence of reduced lead times or improved cash conversion. Revisit only if MRCY quantifies measurable throughput gains in upcoming quarters.
• Set a falsifier alert on FY27 free-cash-flow conversion below ~30% or any Q1/Q2 backlog-to-revenue shortfall versus the implied ramp; that would argue for reducing or exiting the long before the market re-prices the stock on cash-flow disappointment.